A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm

Trial Profile

A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIMA
  • Sponsors Celsion Corporation
  • Most Recent Events

    • 17 Oct 2017 According to a Celsion Corporation media release, an update from this trial was presented at the company's Research and Development (R&D) Day.
    • 04 Oct 2017 According to a Celsion Corporation media release, data from this trial will be presented at a Research and Development (R&D) Day for investors and analysts 2017.
    • 27 Sep 2017 According to a Celsion Corporation media release, the company believes that the regulatory applications will be accepted in South Korea, Taiwan and Vietnam, three other large and important markets for ThermoDox subject to approval in Europe, China or the USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top